Novo Nordisk says CagriSema beat Lilly rival in diabetes trial
Novo Nordisk said CagriSema delivered an estimated average weight loss of 12.4% in a late-stage trial in patients with diabetes, outperforming Eli Lilly’s rival drug.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.